From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
CAS Number
PubChem CID
Chemical and physical data
Formula C12H15N3O2
Molar mass 269.73 g/mol
3D model (JSmol)

Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.[1][2][3][1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.[1]

Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%).[1][4] It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity.[1][4] Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.[4][5]

See also[edit]


  1. ^ a b c d Wolf WA (July 2003). "SLV-308. Solvay". Current Opinion in Investigational Drugs (London, England : 2000). 4 (7): 878–82. PMID 14619412. 
  2. ^ "Search of: pardoprunox - List Results -". 
  3. ^ Bronzova J, Sampaio C, Hauser RA, et al. (March 2010). "Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 25 (6): NA–NA. PMID 20198713. doi:10.1002/mds.22948. 
  4. ^ a b c Glennon JC, Van Scharrenburg G, Ronken E, et al. (December 2006). "In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist". Synapse. 60 (8): 599–608. PMID 17001660. doi:10.1002/syn.20330. 
  5. ^ Gottwald MD, Aminoff MJ (July 2008). "New frontiers in the pharmacological management of Parkinson's disease". Drugs of Today (Barcelona, Spain : 1998). 44 (7): 531–45. PMID 18806903. doi:10.1358/dot.2008.44.7.1217105. 

Further reading[edit]